Minerva Neurosciences, Inc. — Q3 2014 Form 10-Q
Reporting period: Three and nine months ended September 30, 2014. The unaudited results reflect a clinical-stage biopharmaceutical company with no approved products and no product revenue. Comparisons with 2013 are affected by the Sonkei merger in November 2013, the Mind-NRG acquisition in February 2014, and the July 2014 IPO.
Financial performance and position
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $24.7 million | $0.2 million | $39.9 million | $0.5 million |
| General and administrative expense | $2.4 million | $0.3 million | $7.5 million | $0.6 million |
| Net loss | $27.2 million | $0.5 million | $49.5 million | $1.1 million |
| Net loss per share, basic and diluted | $1.53 | $0.12 | $4.58 | $0.29 |
| Operating cash used | Not provided quarterly | Not provided quarterly | $30.9 million | $1.0 million |
- Cash and cash equivalents were $23.6 million at September 30, 2014, compared with $1.8 million at December 31, 2013. Management expected cash to fund operations through the end of 2015, but said additional capital would be required to fully fund development.
- Financing provided $51.6 million net cash in the first nine months, principally from the IPO and concurrent private placements. Investing provided $1.1 million, mainly cash acquired with Mind-NRG.
- Total assets were $73.3 million, including $34.2 million of in-process research and development and $14.9 million of goodwill. Total liabilities were $16.6 million; current liabilities were $3.2 million. No debt instruments remained outstanding at quarter-end.
- Stockholders’ equity was $56.7 million; accumulated deficit was $67.3 million. The filing does not present a gross margin because the company had no revenue.
Changes and notable items
- Q3 R&D expense increased by $24.5 million year over year, primarily from the $22.0 million MIN-202 license fee paid to Janssen, $1.4 million of MIN-202 program costs, and higher MIN-101 formulation-study costs.
- Nine-month R&D included $13.0 million in stock-based compensation, including a $10.5 million charge when 926,604 shares vested following the IPO. Nine-month operating cash use was partly offset by $15.7 million of noncash stock-based compensation.
- The July IPO and concurrent private placements expanded the share count. At September 30, 18,439,482 common shares were outstanding; 2,621,910 stock options were outstanding.
- The company acquired Mind-NRG for consideration valued at $16.5 million in shares, obtaining the MIN-301 program. It also paid the Janssen license fee for MIN-202. The acquired IPR&D and goodwill are subject to impairment assessment.
- Convertible notes and bridge loans were converted or repaid in connection with the IPO. Nine-month interest expense was $2.0 million, largely noncash amortization of the convertible-note discount.
Outlook, risks, and contingencies
- Management expects continued operating losses and negative operating cash flows. The filing identifies substantial doubt about the company’s ability to continue as a going concern without additional financing; if funding is unavailable, operations could be scaled back or discontinued.
- Development priorities include advancing MIN-101 toward a planned Phase IIb study in 2015, while Janssen conducts MIN-202 studies, including a U.S. bioavailability study following FDA completion of its IND review. Further MIN-117 trials depend on financing; MIN-301 was in material scale-up for IND-enabling work.
- Licenses impose development diligence deadlines in April 2015 for MIN-101 and MIN-117. Extensions require $0.5 million payments per year; failure to meet deadlines or extend may allow the licensor to terminate. MIN-101 also carries a $0.5 million development milestone and up to $47.5 million in commercial milestones; MIN-117 has up to $47.5 million in commercial milestones.
- Under the MIN-202 collaboration, Minerva funds 40% of development costs subject to stated caps and may owe royalties; Janssen can opt out at certain milestones or terminate in specified circumstances, including Minerva’s inability to fund its share. Future milestone and royalty obligations are contingent and not included in the contractual-obligations table.
- Material risks include clinical efficacy and safety uncertainty, regulatory delays, dependence on collaborators and contract manufacturers, patent life and protection, competition, and the need for substantial additional capital. The filing states prior studies of MIN-101 and MIN-117 did not show statistically significant favorable differences on all primary, secondary, or exploratory endpoints.
- Disclosure controls and procedures were reported ineffective at September 30, 2014 because of material weaknesses, including inadequate segregation of duties and insufficient resources for complex accounting and disclosure controls. Remediation was underway but not complete. The company reported no material litigation.
- Other commitments include an approximately two-year Waltham office lease, with estimated annual rent of about $0.1 million, and accrued MIN-202 collaboration expenses of $1.4 million.
Key facts for investors to verify
- Whether the $23.6 million cash balance and projected runway through 2015 remain adequate as clinical spending and collaboration obligations progress.
- Progress, enrollment, results, and timing for MIN-101 and MIN-202 studies, and the financing and April 2015 diligence requirements affecting MIN-117.
- Whether additional capital or partnerships can be secured on acceptable terms, and the resulting dilution or changes to development priorities.
- Updates to clinical-trial accruals, stock-based compensation, acquisition purchase-price allocations, and impairment assessments for IPR&D and goodwill.
- Whether material weaknesses in financial reporting controls are remediated and whether subsequent filings report any changes.